Sarepta Therapeutics(DE:AB3A)
€13.72-0.66 (-4.59%)
DE:AB3A
Sarepta Therapeutics stock drug pipeline
€13.72
At close:-0.66 (-4.59%)
Sarepta Therapeutics (AB3A) Drug Pipeline
6 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Sarepta Therapeutics Inc. (DE:AB3A) have in its pipeline
Sarepta Therapeutics DE:AB3A is currently developing the following drugs: Srp-1005, Sirolimus, Glucocorticoids, Elevidys, Antibiotics, Srp-9005, Corticosteroid, Srp-9004, Delandistrogene Moxeparvovec, Plasmapheresis, Srp-9003, Glucocorticoid, Delandistrogene Moxeparvovec, Imlifidase, Delandistrogene Moxeparvovec, Srp-6004, Srp-9003, Vesleteplirsen, Eteplirsen, Srp-4045, Srp-4053. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

